Dublin, Feb. 02, 2022 (GLOBE NEWSWIRE) — The "Global Hydrogel-based Drug System Market By Polymer Origin (Synthetic, Natural and Hybrid), By Delivery Route (Ocular, Subcutaneous, Oral Cavity, Topical and Other Delivery Routes), By Regional Outlook, COVID-19 Impact Analysis Report and Forecast, 2021 – 2027" report has been added to ResearchAndMarkets.com's offering.
The Global Hydrogel-based Drug Delivery System Market size is expected to reach $9.3 billion by 2027, rising at a market growth of 8% CAGR during the forecast period.
Hydrogel refers to the three-dimensional polymeric networks that are proficient in absorbing small to large drug molecules. Thus, it is highly utilized in drug delivery applications. It becomes one of the potential drug delivery systems due to its biocompatibility and biodegradable properties along with an organized release profile. There were several studies conducted across the globe to develop the COVID-19 vaccine and some studies are still going on to develop an effective vaccine with the help of hydrogels, which showcase the future applications and opportunities of hydrogel-based drug delivery systems.
These hydrogel-based delivery systems leverage various therapeutically beneficial results of drug delivery and also showcase several clinical uses. Hydrogels offer spatial & temporal control throughout the release of several therapeutic agents that includes macromolecular drugs, small-molecule drugs, and cells. Due to the controllable degradability, tunable physical properties, and ability to preserve labile drugs from degradation, hydrogels operate as a platform where several physiochemical connections with the encapsulated drugs control their release.
COVID-19 Impact Analysis
The global COVID-19 pandemic has impacted the growth of almost every sector and economy of nations across the globe. The imposed lockdown, travel ban, and other norms have significantly affected various domains of businesses. However, the COVID-19 as positively impacted the hydrogel-based drug delivery system market as various clinical trials of the vaccines require hydrogel, which is contributing its market growth.
In addition, there are many pharma companies that are highly using hydrogel to carry out their research activities regarding new drug development and other clinical studies. Due to this, the demand for hydrogel-based drug delivery systems in the market has increased and further creating new growth avenues for the global market over the forecast period.
Market Growth Factors:
Therapeutic values of the hydrogel-based drug delivery system
In the therapeutic field, drug delivery approaches need exceptional enhancements in developing safe transport systems to attain the required therapeutic effect and to eliminate the side effects. Biomimetic strategies including polymers explain advanced industrial products orientated to aimed therapy and controlled release.
Increasing clinical trials of various medicines, therapies, and vaccines
There are an increasing number of diseases prevailing across the globe, which needs proper medication facilities to improve patients' health. In addition, the growing prevalence of chronic diseases is contributing to the increased demand for better medications, therapies, and vaccines. The outbreak of the global pandemic has also accelerated the number of clinical trials going on across the globe.
Market Restraining Factor:
Complicated manufacturing process
The development process of these hydrogel-based drug delivery systems with constant surface area is very complex, which is estimated to hamper the growth of the market. In addition, it becomes difficult for the companies to manufacture these systems for further usage due to their complex design. It is expected to further restrict the adoption of these systems by various companies.
Polymer Origin Outlook
Based on Polymer Origin, the market is segmented into Synthetic, Natural and Hybrid. Hydrogel-based drug delivery systems are manufactured by using synthetic polymer and are becoming more popular with wide acceptance than naturally derived polymer due to the greater drug absorbing capability, improved lifetime, enhanced mechanical properties, and controllable degradation features. Poly starch, vinylpyrrolidone, and acrylic acid are broadly utilized synthetic polymers in drug delivery applications.
Delivery Route Outlook
Based on Delivery Route, the market is segmented into Ocular, Subcutaneous, Oral Cavity, Topical and Other Delivery Routes. The ocular segment garnered the maximum revenue share in the hydrogel-based drug delivery system marker in 2020. Hydrogels are generally utilized in ocular drug delivery applications as the hard and contact lenses are manufactured with the help of hydrogel films. Thus, it becomes easy to include therapeutic drugs into contact lenses.
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Asia Pacific region is anticipated to register the fastest growth rate in the hydrogel-based drug delivery system during the forecast period. The existence of a huge target population, enhancing access to healthcare, boosting demand for improved medical care in several therapeutic fields, and growing demand to reduce healthcare costs are among the major factors surging the market growth during the forecast period. Nations like India, China, and South Korea are some of the major markets, which is expected to create bright growth prospects in this region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Bausch Health Companies, Inc., Medtronic PLC, Galderma S.A., Endo International PLC, Ferring Holdings SA, Akorn Operating Company LLC, Tolmar Pharmaceuticals, Inc., Blairex Laboratories, Inc., and Ocular Therapeutix, Inc.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Hydrogel-based Drug Delivery System Market by Polymer Origin
3.1 Global Synthetic Market by Region
3.2 Global Natural Market by Region
3.3 Global Hybrid Market by Region
Chapter 4. Global Hydrogel-based Drug Delivery System Market by Delivery Route
4.1 Global Ocular Market by Region
4.2 Global Subcutaneous Market by Region
4.3 Global Oral Cavity Market by Region
4.4 Global Topical Market by Region
4.5 Global Other Delivery Routes Market by Region
Chapter 5. Global Hydrogel-based Drug Delivery System Market by Region
Chapter 6. LAMEA Hydrogel-based Drug Delivery System Market
Chapter 7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental &Regional Analysis
7.1.4 Research & Development Expenses
7.2 Bausch Health Companies, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
126.96.36.199 Partnerships, Collaborations, and Agreements:
188.8.131.52 Product Launches and Product Expansions:
7.3 Medtronic PLC
7.3.1 Company overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.4 Galderma S.A.
7.4.1 Company Overview
7.4.2 Recent strategies and developments:
184.108.40.206 Partnerships, Collaborations, and Agreements:
220.127.116.11 Approvals & Trials:
7.5 Endo International PLC
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental Analysis
7.5.4 Research & Development Expenses
7.6 Ferring Holdings SA
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research and Development Expense
7.7 Akorn Operating Company LLC
7.7.1 Company Overview
7.7.2 Recent strategies and developments:
18.104.22.168 Approvals & Trials:
7.8 Tolmar Pharmaceuticals, Inc.
7.8.1 Company Overview
7.9 Blairex Laboratories, Inc.
7.9.1 Company Overview
7.10. Ocular Therapeutix, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Research & Development Expenses
7.10.4 Recent strategies and developments:
22.214.171.124 Partnerships, Collaborations, and Agreements:
126.96.36.199 Approvals & Trials:
For more information about this report visit https://www.researchandmarkets.com/r/fweunp
Yahoo Finance's Jared Blikre breaks down quarterly earnings for Google parent company Alphabet.
Vaccine maker Novavax (NASDAQ: NVAX) has fallen harder than the broader market of late, dropping by 36% in the past three months alone. Meanwhile, Novavax's shares are trading at $95.22. Although Novavax's stock has been somewhat affected by factors outside of its control, the company also made several blunders of its own.
Artificial intelligence-based lending platform Upstart's (NASDAQ: UPST) stock attracted a lot of market attention last year, with its stock price catapulting nearly 700% by the end of October. The market in general is seeing a shift from hot tech stocks to more traditional value stocks, such as Visa (NYSE: V). Visa stock is already up about 7.5% in 2022 while Upstart stock is down a depressing 27.3%.
As of 10 a.m. ET, PayPal shares were down by 25% to a new 52-week low. As you might expect, PayPal's steep decline is earnings-related. PayPal released its fourth-quarter and full-year 2021 results after the market closed on Tuesday, and to put it mildly, investors weren't too impressed.
Macy's (NYSE: M) is scheduled to report fourth-quarter earnings on Feb. 21. Macy's digital business has impressed enough to attract potential suitors. In its most recent quarter, ended Sept. 30, Macy's digital sales increased 19% versus the same time last year.
Alphabet Inc. followed in the footsteps of Apple Inc. and Tesla Inc. on Tuesday, by making its stock seem more affordable through a 20-to-1 stock split, the first split in eight years for the internet ad and search giant.
The share slide set the stock up for its lowest opening since May 2020, as PayPal also listed out a number of other factors hurting its performance, including high inflation, the end of stimulus checks and the impact of the ongoing supply chain issues on cross-border volumes. At least 11 analysts cut their price targets on the stock and BTIG downgraded its recommendation to "neutral" from "buy". PayPal's operating agreement with eBay, its former parent, has ended and the online marketplace's transition to its own payments platform is impacting transaction volumes, the company said on Tuesday.
AT&T's days as a top dividend S&P 500 stock are numbered. But luckily, lovers of rising and high dividends have a new king.
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of September 30th, when the S&P 500 Index was trading around the […]
SeaWorld made an unsolicited buyout offer for the regional amusement park operator. Is your portfolio tall enough to ride?
Moor Insights & Strategy CEO and Chief Analyst Patrick Moorhead joins Yahoo Finance Live to break down AMD's quarterly earnings and the outlook for chip shortages.
Electric vehicle (EV) stocks saw a broad-based correction in January. Workhorse Group (NASDAQ: WKHS) stock fell 22.5% for the month, according to data provided by S&P Global Market Intelligence. Nikola (NASDAQ: NKLA) stock fell 18.6%, and Lordstown Motors (NASDAQ: RIDE) stock fell 13% in January.
(Bloomberg) — Alphabet Inc. announced a 20-for-1 stock split in the form of a one-time special stock dividend, aiming to draw a wider audience for its shares.Most Read from BloombergAlphabet Stock Split Aimed at Bringing Google Shares to MassesTeen Who Demanded $50,000 From Elon Musk Is Now Targeting More Billionaire JetsSeaWorld Makes $3.4 Billion Takeover Bid for Cedar FairBe Warned — the Turbulence This Time Is DifferentCovid-Infected HIV Patient Developed Mutations, Study Shows“The reason f
Yahoo Finance's Ines Ferre details Amazon's outlook as analysts pay extra attention to its cloud and Prime services, Starbucks' earnings estimates, and AMC releasing preliminary quarterly revenues.
PayPal Holdings Inc.'s rough stretch looks set to continue Wednesday after the payment-technology company delivered an outlook that highlighted spending pressures and brought a strategic change in the way the company will approach user growth.
Let's take a look at Viatris' fundamentals and valuation to answer these questions. What led Viatris' Board of Directors to hand out a huge raise to shareholders? Viatris' average analyst estimate for non-GAAP earnings per share (EPS) is $3.71 for 2021.
PayPal’s fourth-quarter earnings, and particularly its disappointing outlook, are spooking investors.
Stock of the utilities company fell almost 30% in premarket trading on Wednesday after completing the spinoff for its power generation and competitive energy business.
A year ago, office worker Keith Gill shot to global notoriety when his "Roaring Kitty" YouTube persona stoked a trading frenzy with bullish bets that propelled shares of retailer GameStop to eye-popping gains and saddled hedge funds that had bet against the stock with billions of dollars in losses. Gill has returned to obscurity: albeit much richer thanks to his GameStop positions that at one point reached $48 million in value. The Massachusetts securities regulator is still probing Gill's activities around the Reddit rally, a spokeswoman said.
We chat with David Donabedian, chief investment officer at CIBC Private Wealth U.S., who says single-digit gains for the S&P 500 may be the best we get this year.